The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Zactran exceeded the risks for the therapeutic and preventive treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni, (the presence of the disease in the herd should be established before preventive treatment) and recommended that Zactran should be given a marketing authorisation.